Zacks: Analysts Set $10.00 Price Target for Check Cap Ltd (NASDAQ:CHEK)

Shares of Check Cap Ltd (NASDAQ:CHEK) have received an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has given a strong buy rating to the company.

Brokerages have set a 12 month consensus price target of $10.00 for the company and are expecting that the company will post ($0.43) EPS for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 73 out of 256 based on the ratings given to related companies.

CHEK has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Check Cap in a research report on Wednesday, July 10th. Zacks Investment Research raised shares of Check Cap from a “sell” rating to a “hold” rating in a research report on Friday, May 17th.

An institutional investor recently raised its position in Check Cap stock. Renaissance Technologies LLC grew its position in Check Cap Ltd (NASDAQ:CHEK) by 24.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 307,468 shares of the medical research company’s stock after acquiring an additional 60,026 shares during the period. Renaissance Technologies LLC owned about 19.16% of Check Cap worth $652,000 at the end of the most recent quarter.

Check Cap stock traded up $0.04 during mid-day trading on Friday, reaching $2.10. The company’s stock had a trading volume of 18,100 shares, compared to its average volume of 193,627. The company has a market capitalization of $3.33 million and a price-to-earnings ratio of -0.80. Check Cap has a 12 month low of $1.62 and a 12 month high of $4.36. The business’s 50 day simple moving average is $2.00 and its 200 day simple moving average is $2.29.

Check Cap (NASDAQ:CHEK) last released its earnings results on Wednesday, August 7th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.05. As a group, analysts predict that Check Cap will post -1.66 earnings per share for the current fiscal year.

Check Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Featured Article: Debt-To-Equity Ratio

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.